ADAMAX
Cognitive
In short
- A research-market trade name, not a defined compound with an established chemical identity.
- Generally described as an adamantane-modified analogue related to the Semax/ACTH fragment family.
- There is NO published research on this compound under this name — not preclinical, not clinical, not pharmacokinetic.
- Because vendors do not consistently specify the structure, different products sold as ADAMAX may not be the same molecule.
- This is the least characterised entry in the library.
Structure
ADAMAX is a research-market trade name rather than a chemical identifier, generally referring to an N-adamantyl analogue related to the Semax/ACTH fragment family. PubChem has no entry under this name, and the exact structure sold under it is not consistently specified by vendors.
How it works
Vendor descriptions place ADAMAX in the family of ACTH(4-10)-derived peptides related to Semax, modified with an adamantane group. Adamantyl modification is a recognised medicinal chemistry approach for increasing lipophilicity and membrane penetration — bromantane uses the same strategy.
The proposed mechanism by analogy would be BDNF/NGF upregulation as described for Semax.
This is inference from a name and a family resemblance, not from any characterisation of the compound itself. No published work establishes what it does, or reliably what it is.
What the research shows
No published results of any kind exist for this compound.
All reports are anecdotal, and they describe a product whose composition is not verifiable.
Dosing in the literature
Figures below are quoted from published studies, with the species or population they were measured in. They are records of what was studied, not recommendations.
No published dosing data for this compound.
Commonly reported ranges
These are amounts people report using. They are not from any study, have not been evaluated for safety, and are reproduced here only because they circulate widely and are better seen alongside the evidence than instead of it.
| Reported by | Amount | Route |
|---|---|---|
| Commonly reported | 100–300 µg daily | intranasal |
There is no literature dosing because there is no literature. There is also no assurance that two vials sold under this name contain the same substance, which makes even anecdotal reports difficult to interpret across sources.
Handling and storage
Typically supplied lyophilised for reconstitution and intranasal use, following Semax conventions.
Nothing about route, dose, timing, or duration has any evidential basis.
Side effects
No safety data exists in any form — no human study, no animal study, no toxicology.
Community reports are sparse and unverifiable.
The compounding problem here is identity: without knowing what is in the vial, adverse effects cannot be attributed and safe use cannot be reasoned about at all.
Combinations
No interaction data. Combining an unidentified compound with anything else is not a stack that can be reasoned about.
Research status
None published. Searches under this name return vendor listings rather than scientific literature.
This is the clearest case in the library of a product existing entirely as a market offering rather than as a characterised compound.
Legal status
Not approved in any jurisdiction and not characterised anywhere in the regulatory literature. Sold for research use only. Because the name does not map to a specified structure, it is not even clear which regulatory framework would apply to it.
WADA status
Not specifically named on the Prohibited List. Falls under WADA class S0, which prohibits any pharmacological substance not currently approved by any governmental regulatory health authority for human therapeutic use. Treat it as prohibited in sport.
Conclusion
ADAMAX is a trade name with no published research behind it and no consistently specified structure.
Everything else in this library can at least be described accurately. This one cannot, and that is the most important thing to know about it.
Sources
Track your own ADAMAX protocol
Peppers logs your doses, models your levels from this half-life, tracks your vials and tells you when you will run out. Free on iPhone.
Reference and educational information only. Not medical advice. Nothing here diagnoses, treats, or prescribes, and nothing here is a recommendation to use any compound. The compounds described are research chemicals and are not approved for human consumption. Legal and anti-doping status change — the review date above is when these claims were last checked. Talk to a qualified clinician about anything you intend to take.